Profound Medical PROF 深 沪
等待开盘 08-28 09:30:00 美东时间
6.96
-0.150
-2.11%
华盛通- 最 高7.165
- 今 开7.14
- 成交量 4.84万股
- 最 低 6.87
- 昨 收 7.11
- 总市值 2.54亿
- 52周最高 8.95
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 3.76
- 委 比 22.52%
- 总股本 3653.26万
- 历史最高 28.97
- 量 比 0.40
- 振 幅 4.15%
- 历史最低 3.10
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Profound Medical names interim CFO
Profound Medical (PROF) promoted Matthew Sobczyk, its corporate controller since 2020, to interim chief financial officer, effective immediately. Sobczyk succeeds Rashed Dewan, who has stepped down as...
08-15 04:46
Profound Medical Announces Management Change
Profound Medical Corp. promotes Matthew Sobczyk to Interim Chief Financial Officer, succeeding Rashed Dewan. The company, a leader in interventional MRI (iMRI) procedures, develops TULSA-PRO for prostate ablation and Sonalleve for non-surgical treatments. These technologies are approved in major markets, offering precise, personalized care. Profound aims to advance MRI-guided therapies globally.
08-14 20:30
Profound Medical Launches Global Prostate Patient Advocacy Community
Profound Medical ( ($TSE:PRN) ) has issued an update. On August 13, 2026, Profo...
08-14 05:26
Profound Medical Sees FY2026 Sales $25.000M vs $26.858M Est
Profound Medical (TSX:PRN) sees FY2026 sales of $25.000 million vs $26.858 million analyst estimate.
08-07 04:47
Profound Medical Highlights New TULSA Quality-of-Life Data
Profound Medical ( ($TSE:PRN) ) has provided an update. On July 24, 2026, Profo...
07-25 00:27
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
Profound Medical Corp. announced results from the CAPTAIN trial showing that the TULSA Procedure preserves penile length better than robotic radical prostatectomy in men with intermediate-risk prostate cancer. At 1 month, no median change in penile length was observed with TULSA, compared to a 0.65 cm reduction after robotic RP, with a statistically significant difference (p<0.001). The TULSA Procedure also demonstrated superior preservation of e...
07-24 14:15
Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
05-15 18:33
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
<p>Telix Pharmaceuticals has entered into collaborations with EDAP TMS and Profound Medical to integrate PSMA-PET imaging with advanced minimally invasive and image-guided therapies for prostate cancer. The aim is to enhance treatment planning, efficacy, and monitoring while reducing side effects. This partnership focuses on emerging therapies like robotic HIFU and MRI-guided TULSA ablation, aiming to personalize care and improve patient outcomes...
05-15 10:30
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Corp. will highlight the TULSA Procedure in four oral presentations at the AUA 2026 Annual Meeting, focusing on MRI-guided prostate cancer ablation. The company also announced plans to integrate PSMA PET molecular imaging with TULSA-PRO to enhance treatment planning and monitoring, aiming to improve precision and patient outcomes. Attendees are invited to visit Profound's booth for demonstrations of TULSA-PRO and MRI technology.
05-14 11:00
Profound Medical Sees FY2026 Sales $25.000M
Profound Medical (CSE2: PRN) sees FY2026 sales of $25.000 million.
05-08 04:51
